Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.

Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang TH, Jin VX, Clinton SK, Luo J, Huang J, Wang Q.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6810-6815. doi: 10.1073/pnas.1718811115. Epub 2018 May 29. Erratum in: Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E9025.

3.

Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.

Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.

Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.

PMID:
27550197
4.

DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.

Moon SJ, Jeong BC, Kim HJ, Lim JE, Kwon GY, Kim JH.

Oncogene. 2018 Mar;37(10):1326-1339. doi: 10.1038/s41388-017-0047-5. Epub 2017 Dec 18.

PMID:
29249800
5.

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.

Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

6.

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM.

Clin Cancer Res. 2017 Aug 15;23(16):4704-4715. doi: 10.1158/1078-0432.CCR-17-0017. Epub 2017 May 4.

7.

Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Magani F, Peacock SO, Rice MA, Martinez MJ, Greene AM, Magani PS, Lyles R, Weitz JR, Burnstein KL.

Mol Cancer Res. 2017 Nov;15(11):1469-1480. doi: 10.1158/1541-7786.MCR-17-0280. Epub 2017 Aug 15.

8.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, Wang GG.

Mol Cell. 2018 Oct 18;72(2):341-354.e6. doi: 10.1016/j.molcel.2018.08.029. Epub 2018 Sep 27.

PMID:
30270106
9.

The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.

Ramamurthy VP, Ramalingam S, Gediya LK, Njar VCO.

FEBS J. 2018 Mar;285(6):1051-1063. doi: 10.1111/febs.14383. Epub 2018 Feb 3.

10.

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21.

11.

Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.

Tommasi S, Pilato B, Carella C, Lasorella A, Danza K, Vallini I, De Summa S, Naglieri E.

Prostate. 2019 Jan;79(1):54-61. doi: 10.1002/pros.23710. Epub 2018 Aug 23.

PMID:
30141201
12.

Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.

Liu L, Lou N, Li X, Xu G, Ruan H, Xiao W, Qiu B, Bao L, Yuan C, Huang X, Wang K, Cao Q, Chen K, Yang H, Zhang X.

Oncol Rep. 2017 Jun;37(6):3651-3659. doi: 10.3892/or.2017.5623. Epub 2017 May 4.

PMID:
28498452
13.

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD.

Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2.

14.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

15.

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.

Li H, Wang Z, Tang K, Zhou H, Liu H, Yan L, Guan W, Chen K, Xu H, Ye Z.

Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23.

PMID:
28753843
16.

Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Krause WC, Shafi AA, Nakka M, Weigel NL.

Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.

17.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

18.

High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.

Djusberg E, Jernberg E, Thysell E, Golovleva I, Lundberg P, Crnalic S, Widmark A, Bergh A, Brattsand M, Wikström P.

Prostate. 2017 May;77(6):625-638. doi: 10.1002/pros.23307. Epub 2017 Feb 1.

PMID:
28144969
19.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

20.

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.

Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.

Prostate. 2016 Dec;76(16):1536-1545. doi: 10.1002/pros.23238. Epub 2016 Jul 30.

PMID:
27473672

Supplemental Content

Support Center